#1 Clinical Trials Search in Europe

Phenoxymethylpenicillin Benzathine

This article discusses a clinical trial investigating the use of Phenoxymethylpenicillin Benzathine, an antibiotic, as part of a treatment strategy for pyogenic vertebral osteomyelitis (PVO). The study aims to determine if early transition to oral antibiotics, including Phenoxymethylpenicillin Benzathine, is as effective as the current standard of prolonged intravenous antibiotic treatment for PVO patients.

Table of Contents

What is Phenoxymethylpenicillin Benzathine?

Phenoxymethylpenicillin Benzathine is an antibiotic medication that belongs to the penicillin group of drugs[1]. It is used to treat various bacterial infections, including a specific type of bone infection called pyogenic vertebral osteomyelitis (PVO). This medication works by killing or stopping the growth of bacteria that cause infections.

Medical Condition Treated

The primary medical condition treated with Phenoxymethylpenicillin Benzathine in this context is pyogenic vertebral osteomyelitis (PVO)[1]. PVO is a serious infection that affects the bones of the spine (vertebrae). The term “pyogenic” means that the infection is caused by pus-forming bacteria. This condition can cause severe back pain, fever, and in some cases, neurological problems if left untreated.

How It Is Used

Phenoxymethylpenicillin Benzathine is typically administered orally, meaning it is taken by mouth[1]. In the context of treating PVO, it may be used as part of a treatment strategy that involves:

  1. Starting with intravenous (IV) antibiotics for a short period (about one week)
  2. Then transitioning to oral antibiotics, such as Phenoxymethylpenicillin Benzathine, for the remainder of the treatment
This approach is being studied to see if it’s as effective as longer courses of IV antibiotics followed by oral antibiotics[1].

Dosage Information

According to the clinical trial information, the maximum daily dose of Phenoxymethylpenicillin Benzathine is 8 million international units (IU)[1]. The maximum total dose over the course of treatment is 672 million IU. The treatment period can last up to 12 weeks.

It’s important to note that these dosages are specific to the clinical trial and may not reflect the typical dosing for all patients. Always follow your doctor’s instructions regarding dosage and duration of treatment.

Alternative Names

Phenoxymethylpenicillin Benzathine is also known by other names, including:

  • Penicillin V Benzathine
  • Benzathine Phenoxymethylpenicillin
These alternative names may be used interchangeably with Phenoxymethylpenicillin Benzathine[1].

Clinical Trial Information

A clinical trial is currently being conducted to study the effectiveness of early transition to oral antibiotics, including Phenoxymethylpenicillin Benzathine, for treating pyogenic vertebral osteomyelitis[1]. The trial aims to determine if switching to oral antibiotics after one week of IV treatment is as effective as the current practice of longer IV treatment followed by oral antibiotics.

The trial is looking at several factors, including:

  • The overall success of treatment
  • The occurrence of treatment-related side effects
  • The length of hospital stays
  • The quality of life of patients during and after treatment
  • The economic impact of early transition to oral antibiotics
This research could potentially lead to changes in how PVO is treated, possibly reducing the need for long hospital stays and decreasing the risks associated with prolonged IV antibiotic use[1].

Aspect Details
Study Title Early shift to oral antibiotic treatment of pyogenic vertebral osteomyelitis – an open label non-inferiority randomized nationwide study
Main Objective To investigate if early transition to oral antibiotics after one week of IV treatment is non-inferior to current guidelines for PVO treatment
Study Drug Phenoxymethylpenicillin Benzathine (among others)
Dosage Maximum daily dose: 8 million IU; Maximum total dose: 672 million IU
Treatment Duration Up to 12 weeks
Primary Endpoint Composite of mortality, unplanned surgery, infection relapse, and extended IV antibiotic need within 6 months post-treatment
Key Secondary Endpoints Adverse events, hospital admission duration, quality of life, economic impact
Inclusion Criteria PVO diagnosis, appropriate IV antibiotic treatment ≤7 days, CRP decrease
Exclusion Criteria Recent PVO episodes, reduced compliance, severe immunocompromise, spinal implants

FAQ

  • What is pyogenic vertebral osteomyelitis (PVO)? Pyogenic vertebral osteomyelitis is an infection of the bones in the spine. It can cause pain, inflammation, and potentially serious complications if left untreated.
  • What is the main goal of this clinical trial? The main goal is to investigate whether switching to oral antibiotics, including Phenoxymethylpenicillin Benzathine, after one week of intravenous treatment is as effective as the current practice of 2-4 weeks of intravenous antibiotics for PVO.
  • Who can participate in this clinical trial? Adults diagnosed with PVO by a physician, based on symptoms and imaging results, who have received no more than 7 days of appropriate intravenous antibiotics and meet other specific criteria can participate.
  • What are some of the exclusion criteria for this trial? Patients with recent PVO episodes, reduced compliance, severe immunocompromise, spinal implants, or hypersensitivity to the study antibiotics are among those excluded from the trial.
  • How will the effectiveness of the treatment be measured? The primary measure of effectiveness will be a composite of factors including mortality, need for unplanned surgery, relapse of infection, and need for extended intravenous antibiotic treatment within six months of completing oral antibiotic therapy.

Ongoing Clinical Trials on Phenoxymethylpenicillin Benzathine

  • Study on Early Oral Antibiotic Treatment for Vertebral Osteomyelitis Using Cefuroxime, Dicloxacillin, and Ceftriaxone for Adult Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Pyogenic vertebral osteomyelitis (PVO): An infection of the bones in the spine, typically caused by bacteria.
  • Phenoxymethylpenicillin Benzathine: An antibiotic medication used to treat various bacterial infections, including those affecting bones.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Oral antibiotic: Antibiotic medication taken by mouth in the form of pills, capsules, or liquid.
  • Non-inferiority: A type of clinical trial design that aims to show that a new treatment is not worse than the standard treatment by more than a pre-specified margin.
  • CRP: C-reactive protein, a blood test marker that indicates inflammation in the body.
  • MRI: Magnetic Resonance Imaging, a medical imaging technique used to produce detailed images of the body's internal structures.
  • PET/CT: A combination of Positron Emission Tomography and Computed Tomography scans, used for detailed imaging of the body.
  • Bacteremia: The presence of bacteria in the bloodstream.
  • Adverse events: Unexpected medical problems that happen during treatment with a drug or other therapy.
  • Quality of life: A measure of an individual's well-being and ability to perform daily activities.
  • Clostridioides difficile: A type of bacteria that can cause severe diarrhea and other intestinal problems, often associated with antibiotic use.

References

  1. http://clinicaltrials.eu/trial/study-on-early-oral-antibiotic-treatment-for-vertebral-osteomyelitis-using-cefuroxime-dicloxacillin-and-ceftriaxone-for-adult-patients/